Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.53 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469295 | 1.00 | PRMT6 (0.68) | PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL3566828 | 0.98 | PRMT6 (0.66) | PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL923368 | 0.98 | PRMT6 (0.66) | PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL13242846 | 0.96 | PRMT6 (0.62) | PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL16760957 | 0.92 | SIGMAR1 (0.56) | PRMT6ALDH1A1SMN1; SMN2TDP1SIGMAR1 | |
| SCHEMBL22538106 | 0.85 | CHKA (0.63) | PRMT6KDM4ESIGMAR1HRH3NCF1 | |
| SCHEMBL264786 | 0.84 | NCF1 (0.71) | PRMT6ALDH1A1SMN1; SMN2KDM4EHRH3 | |
| SCHEMBL30704912 | 0.84 | NCF1 (0.71) | PRMT6ALDH1A1SMN1; SMN2KDM4EHRH3 | |
| SCHEMBL374345 | 0.84 | ALDH1A1 (0.59) | PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL8879213 | 0.84 | SIGMAR1 (0.62) | PRMT6ALDH1A1TDP1SIGMAR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| EP-2190834-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | claimed |
| EP-2065380-A1 | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-03 | — | — | EP | claimed |
| WO-2009024332-A1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | claimed |
| EP-1453831-A1 | 1H-PYRROLO(3,2-B)PYRIDINE-3-CARBOXYLIC ACID AMIDES | Neurogen Corporation (US) | 2004-09-08 | — | — | EP | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| WO-2003044018-A1 | 1H-PYRROLO[3,2-B]PYRIDINE-3-CARBOXYLIC ACID AMIDES | NEUROGEN CORPORATION (US) | 2003-05-30 | — | — | WO | claimed |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE | 2025-07-15 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2021-10-28 | — | — | US | disclosed |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2021-08-10 | — | — | US | disclosed |
| US-5099032-A | Aminopyrroles formed from hydroxypyrroles by displacement | ABBOTT LABORATORIES (US) | 1992-03-24 | — | — | US | disclosed |
| US-4956475-A | REDUCTIVE ACETYLATION OF THE 3-AZIDO DERIVATIVE USING THIOACETIC ACID TO OBTAIN THE CORRESPONDING ACETAMIDE | ABBOTT LABORATORIES (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0331960-A2 | Process for the preparation of enantiomerically homogeneous aminopyrrolidinyl naphthyridine and quinolone carboxylic acids | ABBOTT LABORATORIES (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4859776-A | (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation | ABBOTT LABORATORIES (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0234872-A1 | Carboxamides useful as antiemetic or antipsychotic agents | Erbamont Inc. (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0147044-A2 | Benzofurancarboxamides, process for their preparation and pharmaceutical preparations containing them | ADRIA LABORATORIES INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0132845-A2 | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | PRMT6 375/4885ALDH1A1 2654/4885SMN1; SMN2 4270/4885 |
| US-12358869-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | PRMT6 1958/4885ALDH1A1 2918/4885SMN1; SMN2 3528/4885 |
| US-11084781-B2 | Diarylureas as CB1 allosteric modulators | CNR1, CNR2, GPR18 | PRMT6 1958/4885ALDH1A1 2918/4885SMN1; SMN2 3528/4885 |
| US-20210332007-A1 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR18 | PRMT6 1958/4885ALDH1A1 2918/4885SMN1; SMN2 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.